Mar. 26 at 8:40 PM
$DNLI OK this is real big deal ( Jenniferr )
The clinical development of DNL151 (also known as BIIB122), an oral small molecule inhibitor of LRRK2 for Parkinson’s disease, is currently in a critical phase with a major clinical readout expected in mid-2026.
Denali Therapeutics
+1
The program is a strategic collaboration between Denali Therapeutics and Biogen, who share the global development costs and responsibilities.
Active Clinical Trials (as of March 2026)
LUMA Study (Phase 2b): This is the lead study evaluating the drug's ability to slow disease progression in ~640 participants with early-stage Parkinson’s disease.
Enrollment was completed in 2025.
The study is estimated to reach primary completion in March 2026, with data results anticipated shortly thereafter.
